This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Board, M. Articles by Newsholme, E. A. Search for Related Content PubMed PubMed Citation Articles by Board, M. Articles by Newsholme, E. A.

High K_m Glucose-phosphorylating (Glucokinase) Activities in a Range of Tumor Cell Lines and Inhibition of Rates of Tumor Growth by the Specific Enzyme Inhibitor Mannoheptulose¹

Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, United Kingdom

Differences in modes of control of glycolysis in tumor cells, compared with normal cells, have suggested that phosphofructokinase may not catalyse the rate-controlling step. Instead, hexokinase activity may assume a more important regulatory role. Hexokinase activities are consistently lower than those of phosphofructokinase in tumor cells, and the former enzyme may be saturated with its substrate (M. Board et al., Biochem. J. 265: 503–509, 1990). The present work has focused on the glucose-phosphorylation step in tumor cell glycolysis. A range of eight human tumor cell-lines, one human tumor tissue, and four rat tumor cell lines were found to have an additional glucose-phosphorylating activity, with properties similar to hepatic glucokinase. Maximal activities range from 1.1–20 nmol/min/mg cell protein, and the activity is consistently absent from any untransformed cell line or tissue tested, except rat liver tissue (18 nmol/min/mg cell protein). Tumor cell glucokinase activity has been characterized by its high K_m for glucose (8–11.8 mM); inhibition by the specific glucokinase inhibitor, mannoheptulose (I₅₀, 12.5 mM); and lack of inhibition by 10 mM glucose-6-phosphate. Mannoheptulose also causes inhibition of glucose uptake by tumor cells (25–75% at 30 mM mannoheptulose) and inhibition of rates of growth of cultured tumor cell lines (I₅₀, 21.4 mM). Rates of growth of human tumors in experimental animals are dramatically reduced (by 65–79%) by a dose of 1.7 mg/g mannoheptulose daily for 5 days. The potential of the naturally occurring sugar, mannoheptulose (which is purified from avocados and is assumed to be of low toxicity), as a cancer treatment is discussed.

¹ The work presented in this paper is the subject of patent application number PCT/GB 94/01676 (filed August 1, 1994).

² To whom requests for reprints should be addressed.

Received 2/ 8/95. Accepted 5/24/95.

This article has been cited by other articles:

				J. A. Fulop Integrative Tumor Board: Recurrent Breast Cancer or New Primary? Integr Cancer Ther, September 1, 2003; 2(3): 276 - 283. [PDF]

				G. Helmlinger, A. Sckell, M. Dellian, N. S. Forbes, and R. K. Jain Acid Production in Glycolysis-impaired Tumors Provides New Insights into Tumor Metabolism Clin. Cancer Res., April 1, 2002; 8(4): 1284 - 1291. [Abstract] [Full Text] [PDF]

				W. S. da-Silva, G. L. Rezende, and A. Galina Subcellular distribution and kinetic properties of cytosolic and non-cytosolic hexokinases in maize seedling roots: implications for hexose phosphorylation J. Exp. Bot., June 1, 2001; 52(359): 1191 - 1201. [Abstract] [Full Text] [PDF]

				P. Costelli, L. Tessitore, B. Batetta, M. F. Mulas, O. Spano, P. Pani, F. M. Baccino, and S. Dessì Alterations of Lipid and Cholesterol Metabolism in Cachectic Tumor-Bearing Rats Are Prevented by Insulin J. Nutr., March 1, 1999; 129(3): 700 - 706. [Abstract] [Full Text]